HRP20200859T1 - Meke kapsule kalcifediola - Google Patents
Meke kapsule kalcifediola Download PDFInfo
- Publication number
- HRP20200859T1 HRP20200859T1 HRP20200859TT HRP20200859T HRP20200859T1 HR P20200859 T1 HRP20200859 T1 HR P20200859T1 HR P20200859T T HRP20200859T T HR P20200859TT HR P20200859 T HRP20200859 T HR P20200859T HR P20200859 T1 HRP20200859 T1 HR P20200859T1
- Authority
- HR
- Croatia
- Prior art keywords
- soft capsule
- pharmaceutically acceptable
- pharmaceutical composition
- once
- mixtures
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Carbon And Carbon Compounds (AREA)
- Lubricants (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Paints Or Removers (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Claims (14)
1. Meka kapsula koja sadrži:
a) omotač meke kapsule, pri čemu omotač meke kapsule sadrži:
- 40 do 80 mas.% želatine,
- 10 do 50 mas.% plastifikatora koji je izabran iz grupe koja se sastoji od glicerola, sorbitola, propilen glikola, polietilen glikola, dibutil sebakata, dietil ftalata, dimetil ftalata, triacetina, tributil citrata, trietil citrata, i njihovih smjesa,
količine po masi su izražene u odnosu na ukupnu masu omotača meke kapsule; i
b) farmaceutski sastav koji sadrži:
- kalcifediol,
- uljnu komponentu izabranu iz grupe koja se sastoji od triglicerida srednjeg lanca, izopropil miristrata, C14-C18 alkil alkohola, C14-C18 alkenil alkohola, lanolin alkohola i njihovih smjesa, i
- farmaceutski prihvatljivo organsko otapalo izabrano iz grupe koja se sastoji od etanola, izopropanola, propilen glikola, polietilen glikola, benzil alkohola i njihovih smjesa,
pri čemu omotač meke kapsule inkapsulira farmaceutski sastav i gdje spomenuti farmaceutski sastav je lišen voska.
2. Meka kapsula prema zahtjevu 1, pri čemu farmaceutska formulacija sadrži:
- 0,001 do 0,2 mas.% kalcifediola,
- 80 do 99,9 mas.% uljne komponente, i
- 0,3 do 6 mas.% farmaceutski prihvatljivog organskog otapala;
količine po masi su izražene u odnosu na ukupnu masu kalcifediola, uljne komponente i farmaceutski prihvatljivog organskog otapala prisutnih u farmaceutskom sastavu.
3. Meka kapsula prema bilo kojem od prethodnih zahtjeva, gdje je uljna komponenta izabrana iz grupe koja se sastoji od triglicerida srednjeg lanca, izopropil miristrata, C14-C18 alkenil alkohola, i njihovih smjesa.
4. Meka kapsula prema bilo kojem od prethodnih zahtjeva, gdje je uljna komponenta triglicerid srednjeg lanca, poželjno kaprilni/kaprinski triglicerid , i/ili gdje je farmaceutski prihvatljivo organsko otapalo izabrano iz grupe koja se sastoji od etanola, izopropanola, propilen glikola, polietilen glikola i njihovih smjesa, poželjno etanola.
5. Meka kapsula prema bilo kojem od prethodnih zahtjeva, koja je lišena surfaktanata.
6. Meka kapsula prema bilo kojem od prethodnih zahtjeva, pri čemu farmaceutski sastav dalje sadrži kalcij ili njegov farmaceutski prihvatljiv derivat.
7. Meka kapsula prema bilo kojem od prethodnih zahtjeva, pri čemu farmaceutski sastav dalje sadrži željezo ili njegov farmaceutski prihvatljiv derivat, vitamin B12, vitamin B9, levomefolnu kiselinu ili njenu farmaceutski prihvatljivu sol, i/ili esencijalnu nezasićenu masnu kiselinu, ili njihove smjese.
8. Meka kapsula prema bilo kojem od prethodnih zahtjeva, pri čemu farmaceutski sastav dalje sadrži bisfosfonat.
9. Meka kapsula prema bilo kojem od prethodnih zahtjeva, pri čemu omotač meke kapsule dalje sadrži farmaceutski prihvatljivo sredstvo za zamućivanje i/ili farmaceutski prihvatljivo sredstvo za bojenje.
10. Meka kapsula prema bilo kojem od prethodnih zahtjeva koja sadrži od 200 do 180000 IU kalcifediola.
11. Meka kapsula kako je definirano u bilo kojem od prethodnih zahtjeva za upotrebu u medicini.
12. Meka kapsula kako je definirano u bilo kojem od zahtjeva od 1 do 10 za upotrebu u liječenju i/ili spriječavanju bolesti izabrane iz grupe koja se sastoji od nedostatka vitamina D, demineralizacije kao što je hipokalcemija i hipofosfatemija, bubrežne osteodistrofije, rahitisa, osteoporoze, osteopenije, osteoartritisa, osteoartroze, osteomalacije, hipoparatireoidizma, i upalne bolesti crijeva.
13. Meka kapsula za upotrebu prema zahtjevu 12, pri čemu je meka kapsula za primjenu jednom svaka tri mjeseca, jednom svaka dva mjeseca, jednom mjesečno, jednom svaka tri tjedna, jednom svaka dva tjedna, jednom tjedno, ili jednom dnevno.
14. Postupak za pripremanje meke kapsule kao što je definirano u bilo kojem od zahtjeva 1 do 10, pri čemu spomenuti postupak sadrži:
a) pripremanje smjese koja sadrži kalcifediol; uljnu komponentu; i farmaceutski prihvatljivo organsko otapalo; i opcionalno kalcij ili njegov farmaceutski prihvatljiv derivat, željezo ili njegov farmaceutski prihvatljiv derivat, vitamin B12, vitamin B9, levomefolnu kiselinu ili njenu farmaceutski prihvatljivu sol, esencijalnu nezasićenu masnu kiselinu i/ili bisfosfonat;
b) pripremanje smjese koja sadrži želatinu; plastifikator; vodu; i opcionalno farmaceutski prihvatljivo sredstvo za zamućivanje i/ili farmaceutski prihvatljivo sredstvo za bojenje;
c) stvaranje omotača iz smjese iz koraka b);
d) punjenje omotača sa smjesom iz koraka a), i
e) sušenje kapsule dobivene u koraku d).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382042.8A EP3053598A1 (en) | 2015-02-06 | 2015-02-06 | Calcifediol soft capsules |
| PCT/EP2016/052458 WO2016124724A1 (en) | 2015-02-06 | 2016-02-05 | Calcifediol soft capsules |
| EP16702960.2A EP3204047B1 (en) | 2015-02-06 | 2016-02-05 | Calcifediol soft capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200859T1 true HRP20200859T1 (hr) | 2020-08-21 |
Family
ID=52462260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200859TT HRP20200859T1 (hr) | 2015-02-06 | 2020-05-28 | Meke kapsule kalcifediola |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10525018B2 (hr) |
| EP (3) | EP3053598A1 (hr) |
| JP (2) | JP6427270B2 (hr) |
| KR (1) | KR101971384B1 (hr) |
| CN (2) | CN112843014A (hr) |
| AU (1) | AU2016214336B2 (hr) |
| BR (1) | BR112017010657B1 (hr) |
| CA (1) | CA2967170C (hr) |
| CL (1) | CL2017001335A1 (hr) |
| CO (1) | CO2017004545A2 (hr) |
| CY (1) | CY1122976T1 (hr) |
| DK (2) | DK3689380T3 (hr) |
| EA (1) | EA034821B1 (hr) |
| ES (2) | ES2941385T3 (hr) |
| HR (1) | HRP20200859T1 (hr) |
| HU (1) | HUE050133T2 (hr) |
| LT (1) | LT3204047T (hr) |
| MA (2) | MA52507A (hr) |
| MD (1) | MD3204047T2 (hr) |
| ME (1) | ME03739B (hr) |
| MX (1) | MX367999B (hr) |
| MY (2) | MY189432A (hr) |
| PE (1) | PE20170911A1 (hr) |
| PH (1) | PH12017501350A1 (hr) |
| PL (1) | PL3204047T3 (hr) |
| PT (1) | PT3204047T (hr) |
| RS (2) | RS60467B1 (hr) |
| SI (1) | SI3204047T1 (hr) |
| SM (1) | SMT202000278T1 (hr) |
| WO (1) | WO2016124724A1 (hr) |
| ZA (1) | ZA201703444B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
| CN108542908A (zh) * | 2018-06-08 | 2018-09-18 | 唐飞 | 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用 |
| CR20210158A (es) | 2018-08-31 | 2021-05-21 | Opko Ireland Global Holdings Ltd | Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso |
| CN109662953B (zh) * | 2019-02-18 | 2022-05-10 | 威海金思力生物科技股份有限公司 | 一种维生素d软胶囊及其制作方法 |
| WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
| EP4081221A1 (en) * | 2019-08-22 | 2022-11-02 | Industrial Technologies & Biotechnologies | Hormone d (vitamin d) and its derivatives for the treatment and prevention of cancer |
| CN113559079B (zh) * | 2020-04-28 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 一种软胶囊及其制备方法和用途 |
| CA3198547A1 (en) * | 2020-11-16 | 2022-05-19 | Mark RIDALL | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022224001A1 (en) | 2021-04-22 | 2022-10-27 | Faes Farma, S.A. | Universal dosage regime of 25-hydroxy vitamin d3 |
| CN114159402A (zh) * | 2021-12-21 | 2022-03-11 | 湖州展望天明药业有限公司 | 一种不透明植物胶囊及其制备方法 |
| CN116350598A (zh) * | 2021-12-28 | 2023-06-30 | 人福普克药业（武汉）有限公司 | 一种用于维生素d类药物的成膜组合物及其药物制剂和制备方法 |
| CN114712505B (zh) * | 2022-03-10 | 2023-09-05 | 南方医科大学南方医院 | 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用 |
| WO2024129811A1 (en) * | 2022-12-14 | 2024-06-20 | R.P. Scherer Technologies, Llc | Softgel capsules and a method for preparing the softgel capsules |
| CN116270520A (zh) * | 2023-03-03 | 2023-06-23 | 正大制药（青岛）有限公司 | 一种维生素d胶囊型滴剂及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4532126A (en) * | 1982-05-07 | 1985-07-30 | R. P. Scherer Corporation | Masticatory soft elastic gelatin capsules and method for the manufacture thereof |
| GB8305693D0 (en) | 1983-03-02 | 1983-04-07 | Scherer Ltd R P | Pharmaceutical compositions |
| JPS6335411A (ja) | 1986-07-29 | 1988-02-16 | Tonen Sekiyukagaku Kk | 高純度合成石英の製造方法 |
| US4997824A (en) | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| JPH04288016A (ja) | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 活性型ビタミンｄ３類軟カプセル剤の製造方法 |
| JPH054925A (ja) | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
| JP2684587B2 (ja) | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| JP4070459B2 (ja) * | 1999-08-31 | 2008-04-02 | 中外製薬株式会社 | 軟カプセル剤 |
| US6251426B1 (en) | 1999-09-02 | 2001-06-26 | Banner Pharmacaps, Inc. | Ibuprofen-containing softgels |
| CN100391464C (zh) | 2001-12-03 | 2008-06-04 | 诺瓦西股份有限公司 | 含活性维生素d化合物的药物组合物 |
| US7632518B2 (en) * | 2002-01-15 | 2009-12-15 | Dsm Ip Assets B.V. | 25-hydroxy vitamin D3 compositions |
| WO2003070156A2 (en) | 2002-02-20 | 2003-08-28 | Strides Arcolab Limited | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| US20030158264A1 (en) * | 2002-02-20 | 2003-08-21 | Ramachandran Radhakrishnan | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same |
| AU2003226148A1 (en) | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
| US7438903B2 (en) | 2003-06-06 | 2008-10-21 | Nbty, Inc. | Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| PT103177A (pt) | 2003-09-24 | 2005-03-31 | Bioxell Spa | 1-alfa-fluoro-25-hidroxi-16,23e-dieno-26,27-bis-homo-20-epi-colecalciferol, seus sais ou esteres e sua utilizacao no fabrico de medicamentos |
| US20050142185A1 (en) | 2003-12-29 | 2005-06-30 | Beleno Alfredo B. | Softgel formulations of bisphosphonates bone resorption inhibitors |
| US20050152969A1 (en) | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
| US20050175686A1 (en) | 2004-02-11 | 2005-08-11 | Ramachandran Radhakrishnan | Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule |
| US20060009425A1 (en) | 2004-05-28 | 2006-01-12 | Leticia Delgado-Herrera | Oral formulations of paricalcitol |
| GB2429916A (en) | 2004-06-07 | 2007-03-14 | Strides Arcolab Ltd | Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
| EP1928471A2 (en) | 2005-09-26 | 2008-06-11 | Novacea, Inc. | Prevention and treatment of gastrointestinal and bladder disorders associated with chemotherapy or radiation therapy using active vitamin d compounds |
| US20070098819A1 (en) * | 2005-11-02 | 2007-05-03 | Susan Thys-Jacobs | Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks |
| DK1993559T3 (en) | 2006-02-03 | 2016-10-03 | Opko Renal Llc | Treatment of vitamin D deficiency and MALFUNCTION with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| WO2008097646A1 (en) * | 2007-02-09 | 2008-08-14 | Schering Corporation | Methods to treat and/or prevent mucositis |
| DK2148684T3 (da) | 2007-04-25 | 2013-04-22 | Cytochroma Inc | Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens |
| SI2148661T1 (sl) | 2007-04-25 | 2013-04-30 | Cytochroma Inc. | Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti naosilec |
| PL2321273T3 (pl) * | 2008-07-24 | 2015-05-29 | Wisconsin Alumni Res Found | Podawanie 25-hydroksy-witaminy D3 raz w tygodniu w celu utrzymania podwyższonego stężenia we krwi w stanie równowagi farmakokinetycznej |
| CA2746887C (en) | 2008-12-15 | 2016-07-05 | Banner Pharmacaps, Inc. | Methods for enhancing the release and absorption of water insoluble active agents |
| WO2010117873A2 (en) | 2009-04-06 | 2010-10-14 | Banner Pharmacaps, Inc. | Progesterone solutions for increased bioavailability |
| WO2012047098A1 (en) | 2010-10-04 | 2012-04-12 | Dishman Pharmaceuticals And Chemicals Ltd. | Encapsulated fat-soluble vitamin |
| GB201216385D0 (en) * | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| KR101847947B1 (ko) | 2013-03-15 | 2018-05-28 | 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 | 안정화되고 변형된 비타민 ｄ 방출 제형 |
| EP3053598A1 (en) | 2015-02-06 | 2016-08-10 | Faes Farma, S.A. | Calcifediol soft capsules |
-
2015
- 2015-02-06 EP EP15382042.8A patent/EP3053598A1/en not_active Withdrawn
-
2016
- 2016-02-05 MY MYPI2017702240A patent/MY189432A/en unknown
- 2016-02-05 CA CA2967170A patent/CA2967170C/en active Active
- 2016-02-05 JP JP2017525563A patent/JP6427270B2/ja active Active
- 2016-02-05 PT PT167029602T patent/PT3204047T/pt unknown
- 2016-02-05 SI SI201630778T patent/SI3204047T1/sl unknown
- 2016-02-05 PL PL16702960T patent/PL3204047T3/pl unknown
- 2016-02-05 MA MA052507A patent/MA52507A/fr unknown
- 2016-02-05 MY MYPI2021001039A patent/MY199862A/en unknown
- 2016-02-05 SM SM20200278T patent/SMT202000278T1/it unknown
- 2016-02-05 LT LTEP16702960.2T patent/LT3204047T/lt unknown
- 2016-02-05 EP EP20163569.5A patent/EP3689380B1/en not_active Revoked
- 2016-02-05 EP EP16702960.2A patent/EP3204047B1/en active Active
- 2016-02-05 HU HUE16702960A patent/HUE050133T2/hu unknown
- 2016-02-05 MD MDE20170056T patent/MD3204047T2/ro unknown
- 2016-02-05 ME MEP-2020-108A patent/ME03739B/me unknown
- 2016-02-05 EA EA201791097A patent/EA034821B1/ru unknown
- 2016-02-05 MX MX2017006272A patent/MX367999B/es active IP Right Grant
- 2016-02-05 RS RS20200628A patent/RS60467B1/sr unknown
- 2016-02-05 RS RS20230331A patent/RS64166B1/sr unknown
- 2016-02-05 CN CN202110038958.XA patent/CN112843014A/zh active Pending
- 2016-02-05 DK DK20163569.5T patent/DK3689380T3/da active
- 2016-02-05 ES ES20163569T patent/ES2941385T3/es active Active
- 2016-02-05 US US15/524,174 patent/US10525018B2/en active Active
- 2016-02-05 PE PE2017000841A patent/PE20170911A1/es unknown
- 2016-02-05 BR BR112017010657-4A patent/BR112017010657B1/pt active IP Right Grant
- 2016-02-05 ES ES16702960T patent/ES2738642T3/es active Active
- 2016-02-05 CN CN201680004162.XA patent/CN106999441B/zh active Active
- 2016-02-05 AU AU2016214336A patent/AU2016214336B2/en active Active
- 2016-02-05 MA MA41058A patent/MA41058B1/fr unknown
- 2016-02-05 DK DK16702960.2T patent/DK3204047T3/da active
- 2016-02-05 KR KR1020177012947A patent/KR101971384B1/ko not_active Ceased
- 2016-02-05 WO PCT/EP2016/052458 patent/WO2016124724A1/en active Application Filing
-
2017
- 2017-05-05 CO CONC2017/0004545A patent/CO2017004545A2/es unknown
- 2017-05-18 ZA ZA2017/03444A patent/ZA201703444B/en unknown
- 2017-05-24 CL CL2017001335A patent/CL2017001335A1/es unknown
- 2017-07-28 PH PH12017501350A patent/PH12017501350A1/en unknown
-
2018
- 2018-07-27 JP JP2018141114A patent/JP6697779B2/ja active Active
-
2020
- 2020-05-28 CY CY20201100484T patent/CY1122976T1/el unknown
- 2020-05-28 HR HRP20200859TT patent/HRP20200859T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200859T1 (hr) | Meke kapsule kalcifediola | |
| JP2018184458A5 (hr) | ||
| HRP20171766T1 (hr) | Stabilni farmaceutski pripravak i postupci njegove uporabe | |
| JP2013100317A5 (hr) | ||
| JP6389237B2 (ja) | 非ゼラチン性腸溶性軟質カプセル | |
| AR089441A1 (es) | Capsulas de gelatina/alginato de liberacion retardada que comprenden acidos grasos omega-3 y metodos y usos de las mismas, metodo de manufactura, composicion farmaceutica | |
| JP2015520235A5 (hr) | ||
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| HRP20150918T1 (hr) | Poboljšana stabilna vodena formulacija (e)-4-karboksistiril-4-klorobenzil sulfona | |
| CL2013001017A1 (es) | Composicion detergente en particulas, empacada, que comprende mas del 40% en peso del surfactante detergente, y al menos 70% en numero de las particulas contienen un nucleo con surfactante, y alrededor un recubrimiento soluble en agua en una cantidad entre 10 a 45% en peso de base a la particula recubierta; y procedimiento para el lavado | |
| MX2015011074A (es) | Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma. | |
| HRP20161340T1 (hr) | Formulacije darunavira | |
| RU2017129161A (ru) | Композиции липидов | |
| HRP20160802T1 (hr) | Čvrsti farmaceutski pripravci koji sadrže derivate biopterina i upotreba takvih pripravaka | |
| HRP20171149T1 (hr) | Oralni farmaceutski pripravak koji sadrži tvar za prikrivanje ukusa n-acetilcisteina | |
| HRP20161624T1 (hr) | Produkt ko-mikronizacije koji sadrži ulipristal acetat | |
| HRP20171485T1 (hr) | Farmaceutski pripravci koji sadrže alisporivir | |
| PE20141011A1 (es) | Formulacion farmaceutica que comprende inositol | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| ITMI20072051A1 (it) | Composizione a base di pellet di acido lipoico | |
| JP2007510690A5 (hr) | ||
| SI2470165T1 (en) | Composition of film for coating from solid powdery compounds | |
| AR096725A1 (es) | Formulación de comprimidos masticables que comprende tadalafil o una de sus sales aceptables desde el punto de vista farmacéutico | |
| JPS603045B2 (ja) | １α―ヒドロキシビタミンＤ類軟カプセルの製造方法 | |
| HRP20192328T1 (hr) | Farmaceutski pripravci koji sadrže niske doze lijekova |